Search research articles
Contact Us
Filters
Showing results (51-60 of 251) with videos related to
Page
of 26
Sort By:
American Journal of Hematology
|
May 27, 2015
Increased bone marrow FDG uptake at PET/CT is not a sufficient proof of bone marrow involvement in diffuse large B-cell lymphoma
Hugo J A Adams, Thomas C Kwee
Protein Science : a Publication of the Protein Society
|
October 25, 2000
Insights into nucleotide binding in protein kinase A using fluorescent adenosine derivatives
Q Ni, J Shaffer, J A Adams
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2016
The Need for Prudence When Using <sup>18</sup>F-FDG PET as a Reference Standard for Lymphoma Detection
Hugo J A Adams, Thomas C Kwee
Annals of Hematology
|
April 12, 2017
Assessing baseline bone marrow status in advanced-stage Hodgkin lymphoma: does it have any purpose?
Hugo J A Adams, Thomas C Kwee
International Journal of Radiation Oncology, Biology, Physics
|
March 1, 2017
In Regard to Ceriani et al
Hugo J A Adams, Thomas C Kwee
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 8, 2017
Fact Sheet About Interim and End-of-Treatment <sup>18</sup>F-FDG PET/CT in Lymphoma
Hugo J A Adams, Thomas C Kwee
European Journal of Haematology
|
December 13, 2016
Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis
Hugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2017
Predictive Value of Interim [<sup>18</sup>F]Fluorodeoxyglucose-Positron Emission Tomography in Advanced-Stage Hodgkin Lymphoma Is Not Well Established
Hugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2019
A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma
Hugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2017
Interim Fluorodeoxyglucose Positron Emission Tomography-Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma
Hugo J A Adams, Thomas C Kwee
Page
of 26
Search research articles
Search
Showing results (51-60 of 251) with videos related to
Sort By:
Page
of 26
American Journal of Hematology
|
May 27, 2015
Increased bone marrow FDG uptake at PET/CT is not a sufficient proof of bone marrow involvement in diffuse large B-cell lymphoma
Hugo J A Adams, Thomas C Kwee
Protein Science : a Publication of the Protein Society
|
October 25, 2000
Insights into nucleotide binding in protein kinase A using fluorescent adenosine derivatives
Q Ni, J Shaffer, J A Adams
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2016
The Need for Prudence When Using <sup>18</sup>F-FDG PET as a Reference Standard for Lymphoma Detection
Hugo J A Adams, Thomas C Kwee
Annals of Hematology
|
April 12, 2017
Assessing baseline bone marrow status in advanced-stage Hodgkin lymphoma: does it have any purpose?
Hugo J A Adams, Thomas C Kwee
International Journal of Radiation Oncology, Biology, Physics
|
March 1, 2017
In Regard to Ceriani et al
Hugo J A Adams, Thomas C Kwee
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 8, 2017
Fact Sheet About Interim and End-of-Treatment <sup>18</sup>F-FDG PET/CT in Lymphoma
Hugo J A Adams, Thomas C Kwee
European Journal of Haematology
|
December 13, 2016
Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis
Hugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2017
Predictive Value of Interim [<sup>18</sup>F]Fluorodeoxyglucose-Positron Emission Tomography in Advanced-Stage Hodgkin Lymphoma Is Not Well Established
Hugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2019
A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma
Hugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2017
Interim Fluorodeoxyglucose Positron Emission Tomography-Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma
Hugo J A Adams, Thomas C Kwee
Page
of 26